Cabecera lazomsalas2019 11 08 CBMSO CSIC UAM

Wednesday, 20th November 2019

Physiopathological aspects of glycine transporters in glycinergic neurotransmission: hyperekplexia and pain


Grupo-400 

 


 

 

Carmen Aragón

DSciStaff

DPublications

 

 

 

 

Research summary:

Current work involves the study of functional mechanism, biogenesis, intracellular trafficking, regulation of CNS glycinetransporters, GlyTs (GlyT1 and GlyT2), plasma membrane proteins of neurons and astrocytes responsible for the completion of glycinergic transmission. Gene deletion studies have suggested that modification of glycine transporter activity may be beneficial in treating several human disorders, including neuromotor deficiencies (startle disease, myoclonus), and neuropathic pain. Indeed, mutations in the gene encoding GlyT2 can cause hyperekplexia in humans and congenital muscular dystonia type 2 in calves.

Our recent studies have contributed to the identification of a site in the extracellular vestibule of GlyT2 involved in cation selectivity and glycine transport coupling mechanism by bioinformatics tools and directed mutagenesis (in collaboration with Dr. Antonio Morreale (Bioinformatic Unit, CBMSO).
We are also interested in the study of GlyT2 trafficking as a fundamental mechanism in the control of glycinergic activity as it provides a rapid manner to modulate its activity. In this regard we have defined molecular mechanisms underlying constitutive and PKC-regulated trafficking trough GlyT2 recycles between the cell surface and the cell interior and the role of membrane rafts and protein kinase C-dependent ubiquitination in the process.

In addition we have reported a coordinated regulation of GlyT1 and GlyT2 by P2Y1R that may result in an increase of the inhibitory pathways over the excitatory pathways leading to anti-nociception.

We have recently identified a new dominant mutation in theGlyT2genein eight patients of hyperekplexia. The heterologous expression and characterization of the mutation (Y705C) allowed us to determine changes in traffic kingand biochemical properties and maturation of the mutant transporter.

 

Fig01-300 --------- Fig02-300
Genetic and structural analysis of theY705C (GlyT2) mutant in hyperekplexia patiens. A, Partial sequences of exon 15 from control and patient 1 DNAs, respectively. B, Molecular model ofGlyT2 showing the localization of Tyr-705 in transmembrane domain 11 (TM11).  

 

Co-localization of GlyT2 wild type (A) and mutation of the C-terminal lysine cluster of GlyT2, 4KR (B) withsyntaxin1A and syntenin-1 in transfected hippocampal neurons. Hippocampal neurons were transfected with wild type GlyT2 or with the 4KR mutant at 10 DIV. The cultures were stained for GlyT2 syntaxin1A and syntenin-1 specific antibodies.

     

 



Relevant publications:

  • Giménez, C., Pérez-Siles, G., Martínez-Villarreal, J., Arribas-González, E., Jiménez, E.,  Núñez, E., de Juan-Sanz, J., Fernández-Sánchez, E., García-Tardón, N., Ibáñez, I., Romanelli, V., Nevado, J., James, V.M., Topf., M., Thomas, R.H., Desviat, L.R., Aragón, C., Zafra, F., Rees, M.I., Lapunzina, P., Harvey, R.J., and  López-Corcuera, B.  (2012). A novel dominant hyperekplexia mutation Y705C alters trafficking and biochemical properties of the presynaptic glycine transporter GlyT2". J. Biol. Chem. 287:28986-9002.
  • de Juan-Sanz, J, Núñez, E, López-Corcuera, B and Aragón, C. (2013) “Constitutive Endocytosis and Turnover of the Neuronal Glycine Transporter GlyT2 Is Dependent on Ubiquitination of a C-Terminal Lysine Cluster. PLoS ONE 8(3): e58863.
  • Arribas-González, E., Alonso-Torres, P., Aragón, C. and López-Corcuera, B. (2013). Calnexin-assisted biogenesis of the neuronal glycine transporter 2 (GlyT2). PLoS One. 8(5):e63230
  • de Juan Sanz, J., Núñez, E., Villarejo-López, L., Pérez-Hernández, D., Rodríguez-Fraticelli, A., López-Corcuera, B., Vázquez, J. and Aragón, C. (2013). Na+/K+-ATPase is a new interacting partner for the neuronal glycine transporter GlyT2 that down-regulates its expresión in vitro and in vivo. J Neurosci. 33:14269-81.

 

Awards:

- Carmen Aragón. Académico Correspondiente de la Real Academia Nacional de Farmacia (9 de junio de 2011).

- Jaime de Juan-Sanz. Premio "Juan Abelló" (2012). Concurso científico anual de la Real Academia Nacional de Farmacia. Regulation of the glycinergic neurotransmission during inflammatory pain: A new pathway in the action of Prostaglandin E2 in the spinal cord. de Juan-Sanz, J., Núñez, E., López-Corcuera, B. and Aragón C.


 

Other activities:

- Pertenencia al Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, grupo U751) del Instituto de Salud Carlos III desde 2007.
- Pertenencia al Grupo de Investigación «Implicación de los SistemasGlicinérgico y Glutamatérgico en Patologías del Sistema Nervioso Central» (Jefe del grupo: Cecilio Giménez) perteneciente al Instituto de Investigación Biosanitaria IdiPAZ desde noviembre 2010.



Doctoral Theses:

Jaime de Juan Sanz (2013). Estudio del tráfico intracelular del transportador neuronal de glicina GlyT2: Modulación por lipid rafts, ubiquitinación e interacción con Na/K ATPasa. Universidad Autónoma de Madrid. Directores: Carmen Aragón Rueda y Beatriz López Corcuera.

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

COOKIES POLICY

What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers: